Skip to main content
SENORES PHARMACEUTICALS LIMITED logo

SENORES PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · SENORES ISIN · INE0RB801010 LEI · 984500FQ4CDFAFBBD763 BSE.NS Manufacturing
Open in API
Filings indexed 182 across all filing types
Latest filing 2026-05-14 Investor Presentation
Country IN India
Listing BSE.NS SENORES

About SENORES PHARMACEUTICALS LIMITED

https://senorespharma.com/

Senores Pharmaceuticals Limited is an R&D-driven pharmaceutical organization specializing in the development, manufacturing, and commercialization of complex generic formulations. The company focuses on niche therapeutic segments and specialty products, including oral solids, liquids, and topicals, with a significant emphasis on complex injectables and ophthalmic solutions. Senores leverages its advanced research capabilities to address unmet medical needs in highly regulated global markets, particularly the United States. Its business model integrates end-to-end capabilities from product identification and formulation development to regulatory filing and global distribution. The company is committed to delivering high-quality, affordable healthcare solutions through strategic partnerships and a robust pipeline of value-added medicines designed to improve patient outcomes in specialized clinical areas.

Recent filings

Filing Released Lang Actions
Senores Pharmaceuticals Limited has informed the Exchange regarding Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed slide presentation titled “Investor Presentation for Q4 & FY26,” containing financial highlights, segmental analysis, P&L, balance sheet and cash flow statements, strategic business updates, and forward‐looking commentary. It was filed under SEBI Regulation 30 as an investor presentation. It is not merely a brief earnings release or an announcement of report publication, but the full investor deck itself. Therefore, it best fits the Investor Presentation category.
2026-05-14 English
Investor Presentation
Investor Presentation Classification · 92% confidence The document is titled “Investor Presentation for Q4 & FY26” and explicitly refers to Regulation 30 (LODR) with slides detailing financial and operational highlights, business strategy, segmental performance, and acquisitions. It is a slide-based deck provided to stock exchanges for investor relations rather than a formal earnings release or quarterly report. This matches the definition of an Investor Presentation (Code: IP).
2026-05-14 English
Senores Pharmaceuticals Limited has informed the Exchange regarding statement of Deviation or Variation for quarter ended on March 31, 2026
Regulatory Filings Classification · 78% confidence The document is a compliance submission under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Regulation 32) to stock exchanges, providing a “statement of deviation or variation in utilisation of funds” for the quarter ended March 31, 2026. It is neither an annual/interim report nor an earnings release or dividend notice, but a standard regulatory compliance filing. It does not represent the publication of a new financial report but rather a disclosure to regulators and exchanges. Therefore, it falls under General Regulatory Filings (RNS).
2026-05-14 English
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 81% confidence The document is a compliance filing under SEBI Listing Obligations (Regulation 32) providing the quarterly statement of deviations/variations in the use of IPO proceeds. It is not a financial report (e.g., earnings release, interim report) nor is it an announcement of a new capital issue; rather, it’s a regulatory disclosure mandated by the stock exchanges. It best fits the miscellaneous “Regulatory Filings” category.
2026-05-14 English
Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for the quarter ended March 31, 2026
Regulatory Filings Classification · 89% confidence The document is a Monitoring Agency Report under SEBI Listing Regulations detailing the quarter-end utilization of IPO proceeds. It is not a full annual or interim financial report, call transcript, earnings release, or other specific category. There is no dedicated category for Monitoring Agency Reports, so it falls into the miscellaneous regulatory compliance filings. Therefore it should be classified as Regulatory Filings (RNS).
2026-05-14 English
Monitoring Agency Report
Regulatory Filings Classification · 85% confidence The document is a Monitoring Agency Report submitted under SEBI Listing Obligations (Regulation 32) and SEBI Issue of Capital Regulations (Regulation 41) regarding utilization of IPO proceeds for the quarter ended March 31, 2026. It is a compliance disclosure filed with stock exchanges, not a full interim financial report, earnings release, or board change announcement. It falls under general regulatory filings required by SEBI. Hence it is classified as Regulatory Filings (RNS).
2026-05-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.